← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cnd Life Sciences, Inc.
Scottsdale, AZ
$9,097,247
Total funding
4
Grants
Funding over time
peak $2.3M · FY2020–25$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,097,247 · 4
By mechanism
R44$9,097,247 · 4
Investigators at Cnd Life Sciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Analysis of Cutaneous Phosphorylated alpha-Synuclein to Identify Patients at Risk of Progressing from Essential Tremor to Parkinson's Disease$1,276,662
R44 · FY2025 · NS
A Diagnostic Test for Dementia with Lewy Bodies$1,239,804
R44 · FY2022 · AG
PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for SmallBusiness Innovation Research Grant Applications (Parent SBIR [R43/R44] ClinicalTrial Not Allowed$1,214,227
R44 · FY2020 · NS
PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for SmallBusiness Innovation Research Grant Applications (Parent SBIR [R43/R44] ClinicalTrial Not Allowed$1,198,087
R44 · FY2021 · NS
A Diagnostic Test for Dementia with Lewy Bodies$1,168,467
R44 · FY2023 · AG
Cutaneous Phosphorylated Alpha-Synuclein for Detection of Prodromal Synucleinopathies$1,092,613
R44 · FY2022 · NS
Cutaneous Phosphorylated Alpha-Synuclein for Detection of Prodromal Synucleinopathies$954,862
R44 · FY2024 · NS
Cutaneous Phosphorylated Alpha-Synuclein for Detection of Prodromal Synucleinopathies$952,525
R44 · FY2023 · NS